Skip to main content
main-content

01.12.2014 | Research | Ausgabe 1/2014 Open Access

World Journal of Surgical Oncology 1/2014

The impact of cyclin D1 overexpression on the prognosis of bladder cancer: a meta-analysis

Zeitschrift:
World Journal of Surgical Oncology > Ausgabe 1/2014
Autoren:
Baoming Ren, Wenjun Li, Yanping Yang, Songdi Wu
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1477-7819-12-55) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

SDW and BMR conceived the study concept and participated in its design, data extraction, statistical analysis, manuscript drafting, and editing. WJL participated in the literature research, manuscript drafting, and editing. YPY participated in design and data extraction. All authors read and approved the final manuscript.

Abstract

Background

To evaluate the relationship between cyclin D1 overexpression and bladder cancer prognosis.

Methods

A systematic literature search up to July 27, 2013 was carried out in PubMed and Wanfang databases, and the references of retrieved articles were screened. The hazard ratios (HRs) and their 95% CIs were used to combine the data. Heterogeneity and publication bias were also evaluated.

Results

A total of 15 studies containing 2,591 cases were included. We found that increased cyclin D1 levels were significantly correlated with progression-free survival with a pooled HR estimate of 0.54 (95% CI: 0.32–0.92). There was a significant degree of heterogeneity (I2 = 93.8%, P <0.001). Moreover, subgroup analysis indicated that elevated cyclin D1 levels were significantly associated with overall survival in muscle-invasive bladder patients (HR: 0.95, 95% CI: 0.91–0.99), without a significant heterogeneity in the data (I2 = 0.0%, P = 0.456).

Conclusions

Increased cyclin D1 expression level detected by immunohistochemistry is associated with good progression-free survival for bladder cancer. Because of the limited number of studies, further well-designed prospective studies are warranted to confirm the findings from our study.
Zusatzmaterial
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2014

World Journal of Surgical Oncology 1/2014 Zur Ausgabe

Neu im Fachgebiet Chirurgie

06.05.2021 | DDG-Tagung 2021 | Kongressbericht | Nachrichten

Vor- und Nachteile: Welche Geräte lohnen sich?

28.04.2021 | Wechselwirkungen der Krebstherapie | Interview | Ausgabe 5/2021

Sicher therapieren trotz komplexer Medikation

Interview mit Prof. Dr. Ulrich Jaehde, Leiter der Abteilung Klinische Pharmazie am Pharmazeutischen Institut der Rheinischen Friedrich-Wilhelms-Universität Bonn

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Chirurgie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise